newsfilter
← Latest News
ClinicalTrials.gov·

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction - NCT05312021

Change in NT-proBNP, To evaluate the safety and tolerability in IMR-687 versus placebo (TEAEs: Treatment-emergent adverse events, Change in Baseline to Week 16 in the Kansas City Cardiomyopathy Questionnaire overall summary score, (and 17 more...)